Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Endobronchial Ultrasound for Diagnosis and Staging of Lung Cancer when it is determined to be medically necessary because the criteria shown below are met.

When Policy Topic is covered
Endobronchial ultrasound guidance with transbronchial needle biopsy may be considered medically necessary for the evaluation of peripheral pulmonary lesions in patients with suspected lung cancer when the following criteria are met:

- Tissue biopsy of the peripheral pulmonary lesion is required for diagnosis (see Considerations section)
- The peripheral pulmonary lesion is not accessible using standard bronchoscopic techniques

Endobronchial ultrasound guidance with transbronchial needle biopsy is considered medically necessary for mediastinal staging in patients with diagnosed lung cancer when the following criteria are met:

- The patient is suitable and willing to undergo specific treatment for lung cancer, with either curative or palliative intent (see Considerations section)
- Tissue biopsy of abnormal mediastinal lymph nodes seen on imaging is required for staging and specific treatment planning (see Considerations section)
- Abnormal lymph nodes seen on imaging are accessible by EBUS-TBNA biopsy

When Policy Topic is not covered
Endobronchial ultrasound is considered not medically necessary for diagnosis and staging of lung cancer when the above criteria are not met.

Endobronchial ultrasound is considered investigational for all other indications.
Considerations
Diagnosis and Staging Guidelines
The American College of Chest Physicians published comprehensive, evidence-based clinical practice guidelines on the diagnosis and management of lung cancer in 2013 (Rivera et al, 2013). Key elements of those guidelines relevant to this policy are outlined next.

The general approach to patients who are suspected of having lung cancer begins with a comprehensive history and physical examination. Imaging studies will include a CT scan of the chest and a whole body PET (positron emission tomography) or PET-CT study to seek extrathoracic lesions. A patient’s suitability and desire for curative treatment of a proven lung cancer is the chief consideration in choosing among subsequent management options. These factors in turn will guide the approach to establishing a diagnosis and staging the disease, as follows:

1. Some individuals may prefer no treatment, particularly those with life-limiting comorbid conditions. In such individuals, neither surgical biopsy nor staging is justified. Aggressive surveillance using serial CT may be used to monitor symptoms for palliation.

2. Two categories of patients, who could potentially benefit from curative surgical resection based on the presence of a solitary, locally confined pulmonary lesion and documented absence of extrathoracic metastatic disease, will not proceed to surgery for completely different reasons.
   a. One group would be considered ineligible for surgery due to sufficiently impaired cardiopulmonary function or other comorbidity that precludes general anesthesia.
   b. A second group of individuals would otherwise be eligible for curative surgery but for personal reasons refuse surgical resection.

For either category of patients listed above, surgical diagnostic and staging procedures are contraindicated. Their options include functional imaging (PET, PET-CT, magnetic resonance imaging), CT scan surveillance, and needle-based nonsurgical biopsy, including guided bronchoscopic procedures such as EBUS.

3. Patients who are candidates for curative surgical resection by virtue of documented (PET, PETCT) absence of distant metastatic lesions, locally confined single tumors, and otherwise sound physical condition are eligible for any type of diagnostic and staging procedure.

4. In patients suspected of having lung cancer based on radiographic imaging (CT), functional imaging (PET, PET-CT) and clinical findings (signs and symptoms of lung cancer), a presumptive diagnosis must be confirmed, preferably by the least invasive method, as dictated by the patient’s presentation and desire for definitive treatment.
5. For patients with extensive mediastinal infiltration of tumor and no distant metastases, it is suggested that radiographic (CT) assessment of the mediastinal stage is usually sufficient without invasive confirmation.

6. In patients with discrete mediastinal lymph node enlargement (and no distant metastases) with or without PET uptake in mediastinal nodes, invasive staging of the mediastinum is recommended over staging by imaging alone.

**Description of Procedure or Service**

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
</table>
| Individuals:  
  - With peripheral pulmonary lesions and suspected lung cancer | Interventions of interest are:  
  - Endobronchial ultrasound– guided transbronchial needle aspiration for diagnosis | Comparators of interest are:  
  - Flexible bronchoscopy with transbronchial needle aspiration  
  - Transthoracic (percutaneous) needle aspiration using computed tomography guidance  
  - Mediastinoscopy  
  - Surgical lung biopsy | Relevant outcomes include:  
  - Overall survival  
  - Disease-specific survival  
  - Test accuracy  
  - Test validity  
  - Morbid events |
| Individuals:  
  - With lung cancer and mediastinal lymph nodes seen on imaging | Interventions of interest are:  
  - Endobronchial ultrasound– guided transbronchial needle aspiration for staging | Comparators of interest are:  
  - Flexible bronchoscopy with transbronchial needle aspiration  
  - Transthoracic (percutaneous) needle aspiration using computed tomography guidance  
  - Mediastinoscopy  
  - Surgical lung biopsy | Relevant outcomes include:  
  - Overall survival  
  - Disease-specific survival  
  - Test accuracy  
  - Test validity  
  - Morbid events |

Endobronchial ultrasound (EBUS) is an imaging technique for adjunctive use with standard flexible bronchoscopy. It provides an ultrasound-generated image of the lungs beyond the airway walls, extending to peribronchial structures and distal peripheral lung lesions. The purpose of EBUS is to facilitate navigation to distal regions of the lungs and biopsy of peripheral pulmonary nodules; especially suspected cancerous lesions. Another intended use of EBUS is to localize and facilitate biopsy of the mediastinal lymph nodes as part of staging for non-small-cell lung cancer. Both techniques primarily use transbronchial needle aspiration (TBNA) of lesions to obtain tissue samples.

For individuals who have peripheral pulmonary lesions and suspected lung cancer who receive EBUS-guided TBNA (EBUS-TBNA) for diagnosis, the evidence includes recent systematic reviews, meta-analyses, and 2 small randomized trials. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and morbid events. Evidence supports a conclusion that EBUS-TBNA has diagnostic performance characteristics for solitary pulmonary lesions similar to those of traditional flexible bronchoscopy with transthoracic needle aspiration. The evidence also indicates that the safety profile of EBUS-TBNA may be better than the profile of other techniques, as reflected by pneumothorax and chest tube
insertion rates. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have lung cancer and mediastinal lymph nodes seen on imaging who receive EBUS-TBNA for staging, the evidence includes systematic reviews and meta-analyses. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and morbid events. Evidence from systematic reviews supports a conclusion that EBUS-TBNA exhibits test performance characteristics similar to other needle-based methods used to stage the mediastinum in patients diagnosed with lung cancer. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Background
Lung Cancer
Individuals who are suspected of having lung cancer may present with widely differing signs and symptoms related to the type of cancer (eg, non-small-cell lung cancer [NSCLC] vs small-cell lung cancer), its location within the lung, and the stage of disease (ie, localized, locoregionally advanced, metastatic). All three of the major parameters of type, location, and stage will dictate subsequent management of the cancer, determining whether it is primarily surgical or requires systemic chemotherapy. Early diagnosis of lung cancer is essential because of the uniformly poor prognosis when cancer is diagnosed later in the disease course.

Approximately 75% to 80% of newly diagnosed lung cancers are NSCLC. The clinical presentation and findings on computed tomography (CT) or a fluorine 18 fluorodeoxyglucose positron emission tomography (PET) scan of the chest will typically permit a presumptive diagnosis of lung cancer and differentiation between NSCLC and small-cell lung cancer. If small-cell lung cancer is suspected based on radiographic characteristics and other clinical findings, a diagnosis is made by whatever means is the least invasive (eg, sputum cytology, thoracentesis if an accessible pleural effusion is present, fine-needle aspiration of a supraclavicular node). The diagnostic technique to evaluate suspected NSCLC is usually dictated by the apparent stage of the disease. NSCLC can present with extensive infiltration of the mediastinum, defined as a mass with no visible lymph nodes, or it may present as a solitary pulmonary nodule that may be bronchogenic or peripheral. In any patient with suspected NSCLC, the diagnosis should be established by the method that has the most favorable risk-benefit ratio.

Diagnosis of Peripheral Pulmonary Nodules
Solitary pulmonary lesions are typically identified on plain chest radiographs or chest CT scans, often incidentally. Although most of these nodules will be benign, some will be cancerous. Peripheral lung lesions and solitary pulmonary nodules (most often defined as asymptomatic nodules <8 mm) are more difficult to evaluate than larger, centrally located lesions. There are several options for diagnosis; however, none of the methods is ideal for safely and accurately diagnosing malignant disease in all patients. Sputum cytology is the least invasive approach. Reported sensitivity rates are relatively low and vary widely
across studies, and sensitivity is even lower for peripheral lesions. Sputum cytology, however, has a high specificity, and a positive test may obviate the need for more invasive testing.

Flexible bronchoscopy, a minimally invasive procedure, is the most common approach to evaluating pulmonary nodules. The sensitivity of flexible bronchoscopy for diagnosing bronchogenic carcinoma has been estimated at 88% for central lesions and 78% for peripheral lesions. For small peripheral lesions less than 1.5 cm in diameter, the sensitivity may be as low as 10%, due to the inability to reach into smaller bronchioles.

Transthoracic (percutaneous) needle aspiration, using CT guidance, can be performed for peripheral nodules that are beyond the reach of traditional bronchoscopy. The diagnostic accuracy of transthoracic needle aspiration tends to be as high or higher than that of flexible bronchoscopy for peripheral lesions; the sensitivity and specificity are both greater than 90%. A disadvantage of transthoracic needle aspiration is that a pneumothorax could occur in as many as 15% of patients (range, 1%-15%). Between 1% and 7% will require chest tube insertion. PET scans are also highly sensitive for evaluating pulmonary nodules, yet may miss small lesions less than 1 cm in size. Surgical lung biopsy is the criterion standard for diagnosing pulmonary nodules but is an invasive procedure not indicated for all patients.

**Staging of Lung Cancer and Assessment of Mediastinal Involvement**

The stage of a lung cancer (its extent through the body) at diagnosis will directly impact the management approach for each patient. The first step in staging is to identify whether the patient has the distant metastatic disease (M stage) or if the tumor is confined to the chest; this will determine whether treatment should be aimed at palliation or at a potential cure, respectively. If the primary tumor is confined (T stage), determining whether the mediastinal lymph nodes (N stage) are involved is a crucial factor in guiding therapy.

As with diagnostic procedures, there are a number of options for mediastinal staging. The choice of a noninvasive or invasive staging method is dictated by the patient’s condition and whether he or she can tolerate or will elect surgery. Thus, staging procedures may be based on noninvasive imaging methods (ie, CT or PET, or combined PET-CT), or may be fully invasive, such as mediastinoscopy—a surgical procedure that is performed under general anesthesia and is regarded as the reference standard for staging lung cancer.

Recent advances in technology have led to enhancements that may increase the yield of established needle-based diagnostic methods that represent a third approach, between noninvasive and surgical procedures. CT scanning equipment can be used to guide flexible bronchoscopy and bronchoscopic transbronchial needle biopsy but has the disadvantage of exposing the patient and staff to radiation.
Endobronchial Ultrasound With Transthoracic Needle Aspiration

Among its potential applications, endobronchial ultrasound (EBUS) using ultrasound probes can locate and guide the sampling of pulmonary lesions and mediastinal lymphadenopathy.

EBUS uses 2 distinct types of transducers that have specific uses: radial probe and convex probe.

A radial probe EBUS comprises a 20- or 30-MHz rotating transducer to provide high-resolution 360° radial images. The probe is inserted into the airways via a standard therapeutic bronchoscope. With the use of an ultrathin bronchoscope combined with radial probe EBUS through a guide sheath, an endoscopist can reach and visualize the sixth- to eighth-generation bronchi, whereas a traditional bronchoscope can only reach the fourth-generation bronchi. The use of radial probe EBUS imaging allows the physician to verify visually that a lesion has been reached and to maintain position in the periphery to allow a needle biopsy to be performed for diagnosis.5 These probes do not allow real-time imaging during the biopsy. For biopsy or tissue sampling, the target area is located by radial probe EBUS; the radial probe is subsequently retracted and is replaced with a biopsy or sampling device.

Convex probe EBUS transducers are adjustable within a frequency range of 5 to 12 MHz. Such transducers are incorporated into the structure of a dedicated bronchoscope and provide real-time pie-slice sector views of 50° to 60° parallel to the axis of the bronchoscope. Convex probe EBUS with transbronchial needle aspiration (EBUS-TBNA) also can be used for staging the mediastinal nodes.6 The curved linear probe technology allows real-time visualization and needle aspiration of a lesion. Because EBUS-TBNA of the mediastinal nodes may be performed under conscious sedation, it may be used in patients who are not surgical candidates but for whom accurate staging is needed to guide choice among systemic treatments, particularly targeted systemic agents such as tyrosine kinase inhibitors.7

Regulatory Status
A number of instruments are commercially available to perform EBUS-TBNA for diagnosis and staging of lung cancer. All have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process and are shown in Table 1.

| Table 1. FDA-Cleared Instruments Used to Perform EBUS-TBNA |
|-----------------|--------------------------|-----------------|-----------------|-----------------|
| device Name | Manufacture | Date Cleared | 510(k) | Indications |
| EVIS EXERA Bronchofibervideoscope, Olympus BF type UC160F-OL8 bronchoscope and its diagnostic ultrasound transducer | Olympus Medical Systems | Aug 2004 | K042140 | To provide real-time endoscopic US imaging and US-guided FNA, including the upper airways and tracheobronchial tree |
| EU-M60 EUS EXERA Endoscopic Ultrasound Center | Olympus Medical Systems | Dec 2004 | K04327 | To acquire and to display high-resolution and high-penetration, real-time endoscopic US B-mode |
EBUS: endobronchial ultrasound; EUS: endoscopic ultrasound; FDA: Food and Drug Administration; FNA: fine-needle aspiration; TBNA: transbronchial needle aspiration; US: ultrasound.

Rationale
This evidence review was created in November 2014 and has been updated regularly with searches of the MEDLINE database. The most recent literature update was performed through July 12, 2018.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and
clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Diagnosis of Lung Cancer**

**Clinical Context and Test Purpose**
The purpose of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients who have pulmonary lesions and suspected lung cancer is to isolate and biopsy the lesions in order to diagnose and stage detected cancers.

The question addressed in this evidence review is whether there is sufficient evidence that EBUS-TBNA used to diagnose lung cancer improves the net health outcome compared with standard bronchoscopic techniques. The primary question of interest to the review is as follows: Is EBUS-TBNA as or more accurate than standard techniques and does it offer fewer harms? Whether any improvement in accuracy leads to improved survival outcomes is also of interest, but, due to the lack of published data, that question is not a focus of the review.

The following PICOTS were used to select literature to inform this review.

**Patients**
The relevant population of interest is individuals with peripheral pulmonary lesions (PPLs) and suspected lung cancer.

**Interventions**
The intervention of interest is EBUS-TBNA.

**Comparators**
Because EBUS is intended as an adjunct to standard bronchoscopic techniques, the primary comparator is flexible bronchoscopy with TBNA. EBUS-TBNA can also be compared with other methods for determining whether PPLs are cancerous: transthoracic (percutaneous) needle aspiration using computed tomography (CT) guidance for lesions outside the reach of traditional bronchoscopy, mediastinoscopy, or surgical lung biopsy.

**Outcomes**
Outcomes of interest for diagnostic accuracy include test accuracy, test validity (eg, sensitivity, specificity) and potential harms of testing (eg, pneumothorax and chest tube insertion rates). The primary outcomes of interest for clinical utility are overall mortality and lung cancer-specific mortality.

**Timing**
EBUS-TBNA would be performed after PPLs were identified or when a prior less invasive test was inconclusive.
**Setting**
EBUS-TBNA would be administered in a specialty care setting.

**Technically Reliable**
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Systematic Reviews**
A substantial body of literature exists on the use of radial probe EBUS to diagnose lung cancer in individuals with solitary pulmonary nodules or lesions. Several systematic reviews of the literature have been published. Appendix Table 1 provides a crosswalk of studies included in select reviews.

Han et al (2018) published a systematic review and meta-analysis comparing radial EBUS and CT-guided transthoracic needle biopsy for the diagnosis of pulmonary lesions 3 centimeters or smaller. Twenty-four studies were identified, 9 for EBUS (813 procedures) and 15 for CT (3463 procedures). The pooled diagnostic yield was 75% for EBUS and 93% for CT. For pulmonary lesions 2 centimeters or smaller, the pooled diagnostic yield was 66% and 92% for EBUS and CT, respectively. Complications were less common for EBUS than for CT; only 10 cases of pneumothorax were reported for EBUS while 660 were reported for CT. The review was limited by the following: (1) all EBUS studies were conducted in the same country, (2) study quality was not uniform, (3) different imaging tools were used in the CT group, and (4) possible study selection bias.

Ali et al (2017) published a systematic review and meta-analysis of studies on the accuracy of radial probe EBUS for diagnosing PPLs. Fifty-seven studies reporting on 7872 lesions met the eligibility criteria. The pooled data on diagnostic yield, using 54 studies, was 70.6%. In a subgroup analysis of 25 prospective studies (n=2920 lesions), the pooled diagnostic yield was 72.3% (95% confidence interval [CI], 67.5% to 76.8%). In the 28 studies that reported diagnostic yield separately by lesion size, pooled diagnostic yield was 60.5% for lesions 2 cm or smaller and 75% (95% CI, 72.1% to 79.2%) for lesions greater than 2 cm. The overall complication rate was 2.8%. There was a total of 160 reported complications, 82 pneumothoraces, 61 bleeds, and 17 cases of pneumonia.

The performance of radial probe EBUS in the Ali meta-analysis appears to be at least as high as flexible bronchoscopy for peripheral nodules as reported in an earlier meta-analysis by the American College of Chest Physicians (ACCP; diagnostic sensitivity, 33% for lesions <2 cm, 62% for lesions >2 cm, 57% for all peripheral lesions), which is discussed below.
A systematic review and meta-analysis by Ye et al (2017) focused on fluoroscopy guidance. Reviewers identified 4 studies (total N=461 patients). In a pooled analysis, the overall diagnostic accuracy was significantly higher in the EBUS transbronchial biopsy (TBB) group than in the conventional TBB group (odds ratio, 2.21; 95% CI, 1.42 to 3.44; p<0.001).

ACCP has published 2 reviews. The ACCP reviews indicated that, in general, most of the evidence comes from small retrospective or prospective studies, plus 2 randomized controlled trials (RCTs).

Tables 2 and 3 summarize the characteristics and results of systematic reviews assessing the clinical validity studies using EBUS to diagnose lung cancer.

### Table 2. Characteristics of Systematic Reviews Assessing the Clinical Validity of R-EBUS for Diagnosing Lung Cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Han et al (2018)</td>
<td>2000-2016</td>
<td>24</td>
<td>Patients with small PLs ≤3 cm</td>
<td>4249 (24-795)</td>
<td>Prospective, retrospective</td>
<td>NR</td>
</tr>
<tr>
<td>Ye et al (2017)</td>
<td>2004-2014</td>
<td>4</td>
<td>Patients with PPLs referred for diagnostic bronchoscopy or R-EBUS-guided bronchoscopy</td>
<td>461 (92-145)</td>
<td>Prospective, retrospective</td>
<td>NR</td>
</tr>
</tbody>
</table>

NR: not reported; PL: pulmonary lesion; PPL: peripheral pulmonary lesion; R-EBUS: radial endobronchial ultrasound.

### Table 3. Results of Systematic Reviews Assessing of Radial EBUS for Diagnosing Lung Cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Diagnostic Yield, %</th>
<th>Diagnostic Yield PLs ≤2 cm, %</th>
<th>Overall Complication Rate, %</th>
<th>Pneumothorax, n/N ( %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Han et al (2018)</td>
<td>75</td>
<td>66</td>
<td>10/815 (1.23)</td>
<td>660/3434 (19.23)</td>
</tr>
<tr>
<td>EBUS</td>
<td>69 to 80</td>
<td>55 to 76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computed tomography</td>
<td>93</td>
<td>92</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>90 to 96</td>
<td>88 to 95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ali et al (2017)</td>
<td>70.6</td>
<td>60.5</td>
<td>2.8</td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>68 to 73.1</td>
<td>56.6 to 64.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ye et al (2017)</td>
<td>2.183</td>
<td>5.045</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odds ratio</td>
<td>1.368 to 3.485</td>
<td>2.063 to 12.337</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>0.001</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; EBUS: endobronchial ultrasound.

### Randomized Controlled Trials

Two small randomized trials were identified that evaluated EBUS: one compared its use with TBB and the other, with conventional fluoroscopy-guided flexible...
bronchoscopy. An RCT by Fielding et al (2012) aimed to determine the diagnostic, complication, and patient tolerability rates of EBUS with a guide sheath EBUS and CT-guided percutaneous core biopsy for peripheral lung lesions among patients with visible lesions suspicious of malignancy.\textsuperscript{11} Patients with lesions greater than 1 cm diameter on CT were randomized to guide sheath EBUS biopsy or CT-guided biopsy. Diagnostic sensitivity was 67\% (22/33 cases) for guide sheath EBUS biopsy and 78\% (19/24 cases) for CT-guided biopsy (p>0.1). In those with negative results, 9 patients in the EBUS group had a CT-guided biopsy as a crossover, seven of which were diagnostic. In the CT group, 4 had crossover EBUS biopsy, 3 of which were diagnostic. When both initial and crossover procedures were evaluated, sensitivity for malignancy was 17 (74\%) of 23 for EBUS biopsy and 23 (88\%) of 26 for CT-guided biopsy (p>0.1). For lesions less than 2 cm, a CT-guided biopsy had a significantly better diagnostic yield (80\% vs 50\%, p=0.05). In EBUS biopsy cases, for lesions with an air bronchogram, sensitivity was 89\%. Pneumothorax and intercostal catheter insertion were performed in 3 and 2 cases, respectively, for EBUS, and 4 and 3 cases for CT-guided biopsy (p=0.02 for pneumothorax). Nine unexpected admissions occurred after CT-guided biopsy compared with 3 after guide sheath EBUS biopsy.

In the RCT by Paone et al (2005), patients with identified peripheral lung lesions suspicious as malignancy who could undergo a complete clinical diagnostic follow-up (n=293) were enrolled in the trial and randomized to EBUS-TBB or TBB.\textsuperscript{12} Lung cancer was diagnosed in 61 patients in the EBUS-TBB group and in 83 patients in the TBB group. The sensitivity of EBUS (78.7\%) was significantly higher than TBB (55.4\%; p=0.004). The specificity was 100\% in both groups. Overall, the accuracy was 85\% in the EBUS group and 69\% in the TBB group (p=0.007). The analysis of a subset of patients with lesions greater than 3 cm showed no significant difference in diagnostic ability between the 2 procedures. A considerable decline in TBB sensitivity (31\%) and accuracy (50\%; p<0.000) was observed in lesions less than 3 cm, while EBUS-TBB sensitivity (75\%) and diagnostic yield (83\%; p=0.001) were maintained. A similar difference was observed when the sensitivity of the 2 procedures was compared in lesions less than 2 cm (23\% vs 71\%, p<0.001).

Tables 4 and 5 summarize the characteristics and results of RCTs assessing the clinical validity studies using EBUS to diagnose lung cancer.

**Table 4. Characteristics of RCTs Assessing the Clinical Validity of EBUS for Diagnosing Lung Cancer**

<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fielding et al (2012)\textsuperscript{11}</td>
<td>Australia</td>
<td>1</td>
<td>2007-2011</td>
<td>Patients with PPLs &gt;1 cm</td>
<td>EBUS-GS (n=33) CT-guided biopsy (n=31)</td>
</tr>
<tr>
<td>Paone et al (2005)\textsuperscript{12}</td>
<td>Italy</td>
<td>1</td>
<td>2001-2003</td>
<td>Patients with PPLs</td>
<td>EBUS-TBB (n=87) TBB (n=119)</td>
</tr>
</tbody>
</table>

CT: computed tomography; EBUS-GS: EBUS-guide sheath; EBUS-TBB: endobronchial ultrasound-driven transbronchial biopsy; PPL: peripheral pulmonary lesion; RCT: randomized controlled trial; TBB: transbronchial biopsy.
Table 5. Results of RCTs Assessing the Clinical Validity of EBUS for Diagnosing Lung Cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Sens, %</th>
<th>Spec, %</th>
<th>Acc, %</th>
<th>Sensitivity for PPLs &lt;2 cm, %</th>
<th>Sensitivity for PLLs &lt;3 cm, %</th>
<th>Diagnostic Yield for PPLs &lt;2 cm, %</th>
<th>Pneumothorax, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fielding et al (2012)</td>
<td>74</td>
<td>50</td>
<td>40</td>
<td>50</td>
<td>3 (8.1)</td>
<td>10 (30.3)</td>
<td>3 (8.1)</td>
</tr>
<tr>
<td>CT-guided biopsy</td>
<td>88</td>
<td>80</td>
<td>85</td>
<td>71</td>
<td>75</td>
<td>69</td>
<td>23.3</td>
</tr>
<tr>
<td>p</td>
<td>NR</td>
<td>0.05</td>
<td>0.02</td>
<td></td>
<td></td>
<td>0.004</td>
<td>0.007</td>
</tr>
<tr>
<td>Paone et al (2005)</td>
<td>78.7</td>
<td>100</td>
<td>85</td>
<td>71</td>
<td>75</td>
<td>69</td>
<td>23.3</td>
</tr>
<tr>
<td>TBB</td>
<td>55.4</td>
<td>100</td>
<td>69</td>
<td>23.3</td>
<td>30.7</td>
<td>69</td>
<td>23.3</td>
</tr>
<tr>
<td>p</td>
<td>0.004</td>
<td>NR</td>
<td>0.007</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.01</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Acc: accuracy; CI: confidence interval; CT: computed tomography; EBUS-GS: guide sheath endobronchial ultrasound; EBUS-TBB: endobronchial ultrasound-driven transbronchial biopsy; PPL: peripheral pulmonary lesion; RCT: randomized controlled trial; Sens: sensitivity; Spec: specificity.

The purpose of the gaps tables (see Tables 6 and 7) is to display notable gaps identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of evidence supporting the position statement.

**Table 6. Relevance Gaps**

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fielding et al (2012)</td>
<td>1. Follow-up duration not clear; perhaps 1-3 d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paone et al (2005)</td>
<td>5. Complications (e.g., pneumothorax, chest tube insertions) not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Follow-up duration not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).
Table 7. Study Design and Conduct Gaps

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocationɑ</th>
<th>Blindingb</th>
<th>Selective Reportingc</th>
<th>Data Completenessd</th>
<th>Powerd</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fielding et al (2012)11</td>
<td>1. Unclear</td>
<td>1. No</td>
<td></td>
<td>2. 7/64 (10.9%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>if allocation was</td>
<td>blinding</td>
<td>performed</td>
<td>did not complete the study</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>concealed from</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paone et al (2005)12</td>
<td>1. Unclear if</td>
<td>1. Physicians</td>
<td>2. 15/221 (6.8%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>allocation was</td>
<td>performing procedures</td>
<td>patients lost to follow-up and others unavailable, making treatment groups uneven (87 vs 119)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>concealed from</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

ɑ Selection key: 1. Selection not described; 2. Selection not random or consecutive (ie, convenience).
bBlinding key: 1. Not blinded to results of reference or other comparator tests.
cTest Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.
e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.
f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs or other controlled studies reporting on longer term health outcomes (ie, mortality) were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

A chain of evidence for the clinical utility of EBUS-TBNA as an adjunct to standard bronchoscopy for the diagnosis of lung cancer is based on an examination of the data on diagnostic accuracy and an examination of harms associated with various diagnostic methods.
The available evidence supports a conclusion that EBUS-TBNA has diagnostic performance characteristics for solitary pulmonary lesions similar to those of traditional flexible bronchoscopic techniques with transthoracic needle biopsy. The evidence also indicates the safety profile of EBUS-TBNA may be less risky than other techniques, as reflected by pneumothorax and chest tube insertion rates. For example, as found by Fielding et al (2012; discussed above), although CT-guided biopsy had higher yields in lesions less than 2 cm, EBUS-GS had better tolerability and fewer complications. The evidence does not establish that 1 technique is better than the others. Thus, the chain of evidence suggests that EBUS-TBNA can improve the net health outcome (ie, has a similar benefit to alternative techniques with less harm).

**Section Summary: Diagnosis of Lung Cancer**

Evidence from 3 meta-analyses and 2 RCTs supports a conclusion that EBUS-TBNA has diagnostic performance characteristics for solitary pulmonary lesions similar to those of traditional flexible bronchoscopic techniques with transthoracic needle biopsy. The available evidence also indicates the safety profile of EBUS-TBNA may be better than other techniques (eg, CT-guided biopsy). This evidence does not establish that any technique is better than the others. The choice of technique for biopsy depends on a number of factors, including the size and location of the lesion(s) and the risks of the planned procedure.

**Staging of Lung Cancer**

**Clinical Context and Test Purpose**

The purpose of EBUS-TBNA in patients who have lung cancer is to biopsy the lesions in order to stage the disease.

The question addressed in this evidence review is whether there is sufficient evidence that EBUS-TBNA used for lung cancer staging improves the net health outcome compared with standard bronchoscopic techniques. Specifically, is EBUS-TBNA as or more accurate than standard techniques and does it have fewer harms?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest is individuals with lung cancer and mediastinal lymph nodes seen on imaging.

**Interventions**

The intervention of interest is EBUS-TBNA.

**Comparators**

Because EBUS is intended as an enhancement to standard bronchoscopic techniques, the primary comparator is flexible bronchoscopy with TBNA. EBUS-TBNA can also be compared with other methods for staging lung cancer,
which include positron emission tomography (PET), transthoracic needle aspiration using CT guidance, and mediastinoscopy.

**Outcomes**
Outcomes of interest for diagnostic accuracy include test accuracy, test validity (e.g., sensitivity, specificity) and potential harms of testing (e.g., pneumothorax and chest tube insertion rates). The primary outcomes of interest for clinical utility are overall mortality and lung cancer-specific mortality.

**Timing**
EBUS-TBNA would be performed after lung cancer is diagnosed.

**Setting**
EBUS-TBNA would be administered in a specialty care setting.

**Technically Reliable**
Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Appendix Table 2 provides a crosswalk of studies included in select reviews. El-Osta et al (2018) published a meta-analysis evaluating EBUS-TBNA for nodal staging of non-small-cell lung cancer with radiologically normal mediastinum. Thirteen studies were included, with a total of 1905 patients (range, 57-258 patients). Sensitivity was 49.5%, negative predictive value was 93.0%, and diagnostic odds ratio was 5.069. The meta-analysis was limited by (1) major heterogeneity across included studies, (2) publication bias, (3) a lack of essential data in some studies, and (4) size, location, and histology of tumor were not considered due to inconsistent reporting.

A systematic review, published by Ge et al (2015), compared EBUS-TBNA with mediastinoscopy for the mediastinal staging of lung cancer. Due to the extremely low rate of false-positive results, reviewers assumed that all positive results were true-positives. Thus, they only pooled analyses of sensitivity (with no false-positives, the specificity would be 100%). For the EBUS-TBNA studies, the pooled sensitivity was 83%; for mediastinoscopy, it was 86%. The difference in sensitivity was not statistically significant (p=0.632). Seventeen complications, including 2 pneumothoraces, 2 cases of perioperative bleeding, 1 esophagus injury, and 1 wound infection, occurred in the mediastinoscopy group and only 4 minor injuries occurred in the EBUS-TBNA group. A limitation of the literature selected for the systematic review is that studies were not head-to-head comparisons of staging techniques.
Tables 8 and 9 summarize the characteristics and results of systematic reviews assessing the clinical validity studies using EBUS to stage lung cancer.

### Table 8. Characteristics of Systematic Reviews Assessing the Clinical Validity of EBUS-TBNA for Staging Lung Cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>El-Osta et al (2018)</td>
<td>2006-2017</td>
<td>13</td>
<td>Patients receiving EBUS-TBNA to detect NSCLC with no radiologic mediastinal involvement</td>
<td>1905 (57-258)</td>
<td>Prospective, retrospective</td>
<td>NR</td>
</tr>
</tbody>
</table>

EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration; NR: not reported; NSCLC: non-small-cell lung cancer.

### Table 9. Results of Systematic Reviews Assessing the Clinical Validity of EBUS-TBNA for Staging Lung Cancer

<table>
<thead>
<tr>
<th>Study</th>
<th>Sensitivity, %</th>
<th>Complications, n/N (%)</th>
<th>NPV, %</th>
<th>Diagnostic Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>El-Osta et al (2018)</td>
<td>49.5</td>
<td>93.0</td>
<td>5.069</td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>36.4 to 62.6</td>
<td>90.3 to 95.0</td>
<td>4.212 to 5.925</td>
<td></td>
</tr>
<tr>
<td>Ge et al (2015)</td>
<td>0.83</td>
<td>4/999 (0.4)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>0.79 to 0.87</td>
<td>NR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mediastinoscopy</td>
<td>0.86</td>
<td>17/915 (1.9)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>95% CI</td>
<td>0.82 to 0.90</td>
<td>NR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; NPV: negative predictive value; NR: not reported.

ACCP published a systematic review, conducted by Silvestri et al (2013), with pooled analyses that provided a comprehensive resource for noninvasive and invasive methods to stage the mediastinum, including EBUS-based techniques. Table 10 summarizes the pooled test performance characteristics for a number of staging procedures drawn from the ACCP evidence review.

### Table 10. Pooled Performance Characteristics of Techniques Used to Stage the Mediastinum in Patients With Lung Cancer

<table>
<thead>
<tr>
<th>Technique</th>
<th>N</th>
<th>Cancer Prevalence, %</th>
<th>Sens, %</th>
<th>Spec, %</th>
<th>PPV, %</th>
<th>NPV, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT with contrast enhancement</td>
<td>7368</td>
<td>30</td>
<td>55</td>
<td>81</td>
<td>58</td>
<td>83</td>
</tr>
<tr>
<td>PET alone</td>
<td>4105</td>
<td>28</td>
<td>80</td>
<td>88</td>
<td>75</td>
<td>91</td>
</tr>
<tr>
<td>PET-CT</td>
<td>2014</td>
<td>22</td>
<td>62</td>
<td>90</td>
<td>63</td>
<td>90</td>
</tr>
<tr>
<td>Traditional mediastinoscopy</td>
<td>9267</td>
<td>33</td>
<td>78</td>
<td>(100)²</td>
<td>(100)²</td>
<td>91</td>
</tr>
<tr>
<td>Video-assisted mediastinoscopy</td>
<td>995</td>
<td>31</td>
<td>89</td>
<td>(100)²</td>
<td>(100)²</td>
<td>92</td>
</tr>
<tr>
<td>Mediastinal lymphadenectomy</td>
<td>386</td>
<td>34</td>
<td>81</td>
<td>(100)²</td>
<td>(100)²</td>
<td>91</td>
</tr>
<tr>
<td>Video-assisted thoracic surgery</td>
<td>246</td>
<td>63</td>
<td>99</td>
<td>(100)²</td>
<td>(100)²</td>
<td>96</td>
</tr>
<tr>
<td>Transthoracic needle aspiration (percutaneous)</td>
<td>215</td>
<td>84</td>
<td>94</td>
<td>(100)²</td>
<td>(100)²</td>
<td>NR²</td>
</tr>
<tr>
<td>TBNA</td>
<td>2408</td>
<td>81</td>
<td>78</td>
<td>(100)²</td>
<td>(100)²</td>
<td>77</td>
</tr>
</tbody>
</table>
The data in Table 10 would suggest the grouping of imaging techniques as a whole does not perform as well as the invasive techniques overall. Within the invasive grouping, there seems to be little apparent difference in terms of performance characteristics. Traditional surgical mediastinoscopy has long been considered the criterion standard for staging the mediastinum in patients diagnosed with lung cancer; variants of it are used in specific cases (eg, when the cervical approach does not provide information specific to certain node stations). Mediastinoscopy is indicated mainly for patients who would be candidates for curative surgical resection. The less invasive guided needle-based methods are suitable for nonsurgical candidates or those who refuse surgery, yet require staging to plan specific systemic therapy or radiotherapy. They appear to have very similar performance characteristics based on the ACCP analyses, including EBUS-TBNA.

**Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs or other controlled studies were identified.

**Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

A chain of evidence of the clinical utility of EBUS-TBNA for the staging of lung cancer is based on an examination of the EBUS-TBNA data on diagnostic accuracy and harms associated with various staging techniques. The evidence underlying the pooled accuracy for mediastinal staging is less than optimal. The literature review for staging did not identify any RCT evidence to compare EBUS guidance.
with any other needle-based technique. There are differences among the patient populations and the use of reference standard confirmation of node positivity. The evidence summarized herein supports a conclusion that EBUS-TBNA exhibits test performance characteristics similar to other needle-based methods used to stage the mediastinum in patients diagnosed with lung cancer. Although EBUS-TBNA could be used in patients who are surgical candidates and plan to undergo surgery, it also may be suitable for those who are not eligible for curative resection—or for those who refuse to undertake major surgery but still require staging for planning systemic or radiotherapy. A major advantage of EBUS-based methods is that they can be performed on an outpatient basis under limited sedation if necessary, and thus would be less invasive and less risky than traditional mediastinoscopy. Thus, the chain of evidence suggests that EBUS-TBNA may be more beneficial in certain situations.

**Section Summary: Staging of Lung Cancer**
The literature review on the use of EBUS-TBNA for staging did not identify any RCT evidence that compared EBUS guidance with any other needle-based technique. The evidence summarized herein from systematic reviews supports a conclusion that EBUS-TBNA exhibits test performance characteristics similar to other needle-based methods used to stage the mediastinum in patients diagnosed with lung cancer. Although it could be used in patients who are surgical candidates and plan to undergo surgery, it also may be suitable for those who are not eligible for curative resection or refuse to undertake major surgery but still require staging for planning systemic or radiotherapy. A major advantage of EBUS-based methods is that they are less invasive and less risky than traditional mediastinoscopy.

**Summary of Evidence**
For individuals who have peripheral pulmonary lesions and suspected lung cancer who receive EBUS-TBNA for diagnosis, the evidence includes recent systematic reviews, meta-analyses, and 2 small randomized trials. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and morbid events. Evidence supports a conclusion that EBUS-TBNA has diagnostic performance characteristics for solitary pulmonary lesions similar to those of traditional flexible bronchoscopy with transthoracic needle aspiration. The evidence also indicates that the safety profile of EBUS-TBNA may be better than the profile of other techniques, as reflected by pneumothorax and chest tube insertion rates. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have lung cancer and mediastinal lymph nodes seen on imaging who receive EBUS-TBNA for staging, the evidence includes systematic reviews and meta-analyses. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and morbid events. Evidence from systematic reviews supports a conclusion that EBUS-TBNA exhibits test performance characteristics similar to other needle-based methods used to stage the mediastinum in patients diagnosed with lung cancer. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

National Comprehensive Cancer Network
National Comprehensive Cancer Network guidelines on non-small-cell lung cancer (v.6.2018) state:

“The least invasive biopsy with the highest yield is preferred as the first diagnostic study.... Patients with peripheral (outer one-third) nodules may benefit from navigational bronchoscopy, radial EBUS [endobronchial ultrasound], or transthoracic needle aspiration (TTNA).... Patients with suspected nodal disease should be biopsied by EBUS, EUS [endoscopic ultrasound], navigational bronchoscopy or mediastinoscopy.”15.

American College of Chest Physicians
The American College of Chest Physicians has offered a number of evidence-based guidelines on the use of EBUS-guided needle aspiration of pulmonary lesions for diagnosis of lung cancer1, and mediastinal staging of patients diagnosed with lung cancer (see Table 11).3, A separate guideline and expert panel report (2016) has addressed the technical aspects of EBUS-guided transbronchial needle aspiration and its use outside the setting of lung cancer.16.

Table 11. Guidelines on Use of Endobronchial Ultrasound to Diagnose and Stage Lung Cancer

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis of peripheral pulmonary nodules</td>
<td>1C</td>
</tr>
<tr>
<td>“2.3.2. In patients suspected of having lung cancer, who have extensive infiltration of the mediastinum based on radiographic studies and no evidence of extrathoracic metastatic disease (negative PET scan), it is recommended that the diagnosis of lung cancer be established by the least invasive and safest method (bronchoscopy with TBNA, endobronchial ultrasound-guided needle aspiration [EBUS-NA], endoscopic ultrasound-guided needle aspiration [EUS-NA], transthoracic needle aspiration [TTNA], or mediastinoscopy).”</td>
<td>1C</td>
</tr>
<tr>
<td>“3.3.2.1. In patients suspected of having lung cancer, who have a peripheral lung nodule, and a tissue diagnosis is required due to uncertainty of diagnosis or poor surgical candidacy, radial EBUS is recommended as an adjunct imaging modality.”</td>
<td>1C</td>
</tr>
<tr>
<td>Staging of the mediastinum in patients diagnosed with lung cancer</td>
<td></td>
</tr>
<tr>
<td>“4.4.4.3. In patients with high suspicion of N2,3 involvement, either by discrete mediastinal lymph node enlargement or PET uptake (and no distant metastases), a needle technique (endobronchial ultrasound [EBUS]-needle aspiration [NA], EUS-NA or combined EBUS/EUS-NA) is recommended over surgical staging as a best first test.... <strong>Remark:</strong> In cases where the clinical suspicion of mediastinal node involvement remains high after a negative result using a needle technique, surgical staging (eg, mediastinoscopy, video-assisted thoracic surgery [VATS], etc) should be performed.”</td>
<td>1B</td>
</tr>
</tbody>
</table>

PET: positron emission tomography.
**U.S. Preventive Services Task Force Recommendations**
No U.S. Preventive Services Task Force recommendations for endobronchial ultrasound have been identified.

**Medicare National Coverage**
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**Ongoing and Unpublished Clinical Trials**
Some currently unpublished trials that might influence this review are listed in Table 12.

**Table 12. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td>NCT02719847 Additive Value of EBUS TBNA for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy</td>
<td>150</td>
<td>Mar 2020</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td>NCT00559611 Prospective Comparison of Endobronchial Ultrasound Needle Biopsy Versus Mediastinoscopy for Staging of Mediastinal Nodes in Patients With Clinical Stage IIIA Non-Small Cell Lung Cancer (NSCLC)</td>
<td>53</td>
<td>Mar 2018 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

**REFERENCES**


Billing Coding/Physician Documentation Information

31652 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures (New code 1/1/2016)

31653 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures (New code 1/1/2016)

31654 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to code for primary procedure[s]) (New code 1/1/2016)

ICD-10 Codes

C34.00- Malignant neoplasm of bronchus and lung code range
C34.92
C78.00- Secondary malignant neoplasm of respiratory organs code range
C78.39
D02.20- Carcinoma in situ of bronchus and lung code range
D02.22
D14.30- Benign neoplasm of bronchus and lung code range
D14.32
D38.1  Neoplasm of uncertain behavior of trachea, bronchus and lung
D49.1  Neoplasm of unspecified behavior of respiratory system
J98.4  Other disorders of lung

CPT 31620 deleted as of 12/31/15.

**Additional Policy Key Words**

N/A

**Policy Implementation/Update Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/1/15</td>
<td>New Policy. Endobronchial ultrasound is medically necessary for diagnosis and staging of lung cancer when criteria are met.</td>
</tr>
<tr>
<td>8/1/16</td>
<td>No policy statement changes.</td>
</tr>
<tr>
<td>8/1/17</td>
<td>No policy statement changes.</td>
</tr>
<tr>
<td>8/1/18</td>
<td>No policy statement changes.</td>
</tr>
<tr>
<td>8/1/19</td>
<td>No policy statement changes.</td>
</tr>
</tbody>
</table>

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.